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Aim: To report the long-term results of high-dose-rate (HDR) brachytherapy (BT) boost for
breast cancer patients treated with conservative surgery and radiotherapy.
Materials and methods:Between1995 and2007, 100 early-stage breast cancer patients received
an HDR BT boost after conservative surgery and whole breast irradiation. Ten patients (10%)
received a single-fraction HDR boost of 8–10.35Gy using rigid needles, while 90 (90%) were
treated with a fractionated multi-catheter HDR BT boost. The latter consisted of 3×4Gy
(n=19), 3×4.75Gy (n=70), and 2×6.4Gy (n=1). Breast cancer related events, cosmetic results
and side effects were assessed.
Results: At a median follow-up time of 94 months (range: 8–152) only 7 (7%) ipsilateral breast
failures were observed for a 5- and 8-year actuarial rate of 4.5 and 7.0%, respectively. The 8-
year disease-free, cancer-speciﬁc, and overall survivalwas 76.1, 82.8, and 80.4%, respectively.
Cosmetic outcome was rated excellent in 17%, good in 39%, fair in 33%, and poor in 11%.
Data on late radiation side effects were available for 91 patients (91%). Grade 3 ﬁbrosis and
grade 3 telangiectasia occurred in 6 (6.6%) and 2 (2.2%) patients, respectively. In univariateanalysis only positive margin status had a signiﬁcant negative effect on local control.
Conclusions: HDR BT boost using multi-catheter implants produce excellent long-term local
tumour control with acceptable cosmetic outcome and low rate of grade 3 late radiation side
effects.
© 2009 Wielkopolskie Centrum Onkologii. Published by Elsevier Urban & Partner Sp. z.o.o.. Backgroundver the last decades, breast-conserving surgery (BCS) and
ostoperative radiotherapy (RT) became the standard of care
∗ Corresponding author. Tel.: +36 1 224 8600; fax: +36 1 224 8680.
E-mail address: polgar@oncol.hu (C. Polgár).
507-1367/$ – see front matter © 2009 Wielkopolskie Centrum Onkologii.
oi:10.1016/j.rpor.2010.01.002All rights reserved.
for the treatment of early-stage breast carcinoma.1,2 The stan-
dard technique of RT after BCS is to treat the whole breast by
teletherapy via tangential ﬁelds up to a total dose of 45–50Gy.3The main rationale to give an additional dose of 10–25Gy to
the tumour bed after whole breast irradiation (WBI) was based
on the clinical observation that 67–100% of ipsilateral breast
recurrences originated from the vicinity of the original index
Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Table 1 – Patient and tumour characteristics.
Characteristic n (%)
Mean age (years) 56.7
Range 37–77
Age (years)
<40 5 (5%)
40–50 22 (22%)
>50 73 (73%)
Premenopausal 30 (30%)
Histological type
DCIS 6 (6%)
Ductal 67 (67%)
Lobular 16 (16%)
Ductal + lobular 2 (2%)
Mucinous 4 (4%)
Medullary 2 (2%)
Tubular 1 (1%)
Apocrin 1 (1%)
Metaplastic 1 (1%)
Surgical margins
Positive 5 (5%)
Close (≤2mm) 13 (13%)
Clear (>2mm) 69 (69%)
UK 13 (13%)
Pathologic tumour size (mm)
Mean 18.2
Range 1–35
pTis 6 (6%)
pT1 57 (57%)
pT2 37 (37%)
Pathologic nodal status
pN0 (ALND) 59 (59%)
pN0 (SLNB) 11 (11%)
pN1mi (SLNB) 1 (1%)
pN1a (ALND) 16 (16%)
pN2a (ALND) 7 (7%)
pN3a (ALND) 2 (2%)
pNx (cN0)a 4 (4%)
HG
1 20 (20%)
2 39 (39%)
3 27 (27%)
NAb 6 (6%)
UK 8 (8%)
LVI
Positive 31 (31%)
Negative 60 (60%)
UK 9 (9%)
EIC
Positive 21 (21%)
Negative 58 (58%)
NAb 6 (6%)
UK 15 (15%)
ER status
Positive 59 (59%)
Negative 30 (30%)
UK 11 (11%)
PR status
Positive 54 (54%)
Negative 34 (34%)
UK 12 (12%)
DCIS=ductal carcinoma in situ; UK=unknown; ALND=axillary
lymph node dissection; SLNB=sentinel lymph node biopsy;
HG=histological grade. LVI = lympho-vascular invasion;
EIC=extensive intraductal carcinoma; ER=estrogen receptor;2 reports of practical oncology
lesion.4 To date, three randomized trials have conﬁrmed that a
boost dose of 10–16Gy after 50Gy WBI signiﬁcantly decreased
the local recurrence (LR) rate.4–8 Patient age less than 50
years, close, microscopically positive or unknown surgical
margins, and the presence of an extensive intraductal com-
ponent (EIC) are generally accepted as absolute indications for
boost irradiation.4 However, a controversy still exists regard-
ing the optimal boost technique. Traditionally, low-dose-rate
(LDR) brachytherapy (BT), electrons or photons have been used
to deliver the boost dose to the tumour bed.4,5,8–15 Later, high-
dose-rate (HDR) BThas also been accepted as a safe alternative
boost modality.6,7,12,16–27
2. Aim
A retrospective analysis was performed to report the long-
term results of HDR BT boost for breast cancer patients treated
with BCS and RT at the Hungarian National Institute of Oncol-
ogy (HNIO).
3. Materials and methods
3.1. Surgery, patient and tumour characteristics
Between 1995 and 2007, 100 early-stage breast cancer patients
received an HDR BT boost after conservative surgery and WBI.
All patients underwent wide excision, deﬁned as a resection
of the primary tumour with at least 1 cm of macroscopic free
margin. During surgery, the boundaries of the excision cav-
ity were marked with titanium clips. At least level I–II axillary
dissection was performed for 84 patients (84%) and 12 women
(12%) underwent sentinel lymph node biopsy. For the remain-
ing 4 cases (4%), operated on for pure ductal carcinoma in situ
(DCIS), surgical axillary staging was omitted by the surgeon’s
preference. Patient and tumour characteristics are listed in
Table 1.
3.2. External beam irradiation
All patients received WBI delivered with telecobalt (n=5) or
6–9 MV photon (n=95) beams using wedged tangential ﬁelds
with 2Gy daily fractions (5 fractions/week). The dose was
prescribed to 95% of the dose at the isocentre, which was
located on the central axis CT slice at the midpoint between
the lung–chest wall interface and skin surface. The median
total dose of WBI was 50Gy (range: 30–50Gy). Seventy-ﬁve
out of 100 patients (75%) received the full intended total
dose of 50Gy. In 25 patients (25%) the total dose was lim-
ited to 30Gy (n=1), 38Gy (n=1), 44Gy (n=4), 46Gy (n=10), and
48Gy (n=9) based on the decision of the treating radiation
oncologist. Twenty-ﬁve axillary lymph node-positive patients
(25%) received 44–50Gy (median: 50Gy) regional nodal irradia-
tion using an anterior supraclavicular–axillary 6–9MV photon
ﬁeld.3.3. HDR brachytherapy boost
Interstitial BT boost was performed 2–3 weeks after complet-
ing WBI. Patients were treated with HDR remote afterloading
PR=progesterone receptor. Data presented as number of patients,
with percentage in parentheses, unless otherwise noted.
a Surgical axillary staging was omitted in 4 out of 6 patients with
DCIS.
b NA=not applicable (for DCIS).
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Table 2 – Biologically equivalent HDR fractionation schedules used for brachytherapy boost calculated by the
linear-quadratic model.
Low boost dose group (n=21)
20Gy LDR-equivalent fractionation schemes
(calculated for late effects; ˛/ˇ ratio = 4Gy)
High boost dose group (n=79)
20Gy LDR-equivalent fractionation schemes
(calculated for early effects; ˛/ˇ ratio = 10Gy)
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All intervals were calculated from the date of surgery. The1×8Gy (n=2)
2×5.2Gy (not used)
3×4Gy (n=19)
quipment (microSelectron Classic and V2, Nucletron B.V.,
eenendaal, The Netherlands) using an 192Ir stepping source
ith 370GBq initial activity. The implantations were per-
ormed under local anaesthesia. Pre-implant X-ray simulation
as performed with a template on the breast to deﬁne the
ntrance and exit points of the needles according to the
rojections of surgical clips of the tumour bed using the
eedle-eye-view technique. The planning target volume (PTV)
as deﬁned as the excision cavitywith amargin of 1–2 cm. Fol-
owing pre-implant simulation 3–19 guide needles (median:
.5) were inserted into the previously targeted volume in a
riangular setting using template guidance with 13–15mm
pacing between the needles. Single-, double-, triple-, and
our-plane implants were performed on 3 (3%), 82 (82%), 11
11%), and 4 (4%) of the patients, respectively. The HDR frac-
ionation scheduleswere calculatedusing the linear-quadratic
LQ) model with an ˛/ˇ ratio of 4Gy for late and 10Gy for
arly effects. 28 The biologically equivalent HDR fractionation
chedules used for the HDR BT boost calculated by the LQ
odel are summarized in Table 2. For the ﬁrst 21 patients
low boost dose group), the boost dose was calculated to be
quivalent to the late effects of 20Gy LDR radiation. Since seri-
us side effects were not observed, the total boost dose was
ncreased for the next 79 patients (high boost dose group) to
e equivalent to the early (tumour) effects of 20Gy LDR treat-
ent. Overall, 10 patients (10%) received a single-fraction HDR
T boost of 8Gy (n=2) and 10.35Gy (n=8) using rigid needles,
hile 90 (90%) were treated with fractionated HDR sched-
les using ﬂexible plastic tubes (multi-catheter technique).
he latter consisted of 3×4Gy (n=19), 3×4.75Gy (n=70), and
×6.4Gy (n=1) using 1 fraction daily over 2–3 days. Patients
eceiving 2 or 3 fractions stayed in hospital for 1–2 nights.
or fractionated multi-catheter treatments the guide needles
ere replaced with plastic catheters and secured with ﬁxation
uttons. The dose planning was based on three-dimensional
econstruction of the catheters (or needles), surgical clips, and
kin points with the help of two post-implant isocentric X-
ay images, using the variable angle reconstruction technique.
he active source positions and reference dose points were
eﬁned individually in each catheter, and optimization of the
well times to dose points and geometry was performed. The
ost peripheral active source positions were kept at a min-
mum of 10mm distance from the skin points, limiting the
aximal skin dose to 60% of the prescribed dose. The dis-
ance of the dose points from the catheters was 5–13mm,
arying from catheter to catheter to achieve 100% isodose sur-
ace cover for all surgical clips with a margin of 1–2 cm. For
he assessment of implant quality, cumulative dose-volume
istogram and dose non-uniformity ratio (DNR) were used.
he mean volume encompassed by the 100% isodose surface
as 43.5 cm3 (range: 18.9–104.2 cm3). The mean DNR was 0.491×10.35Gy (n=8)
2×6.4Gy (n=1)
3×4.75Gy (n=70)
(range: 0.30–0.58). Pre- and post-implant CT scans were used
for BT treatment planning only for 5 patients (5%).
3.4. Adjuvant systemic therapy
Systemic therapy was given according to the actual institu-
tional treatment protocol. Adjuvant therapy has evolved over
the years. Systemic therapy for low-risk patients with pT1
pN0 tumours was optional rather than mandatory before the
publication of the guidelines of the 1998 St. Gallen’s Con-
sensus Conference.29 Since 1999, all patients with tumour
size >10mm have received adjuvant systemic therapy. Thus,
overall, 62 patients (62%) received systemic therapy, 42 (42%)
hormone therapy, 9 (9%) chemo- and hormone therapy,
and 11 (11%) chemotherapy alone. Hormone therapy con-
sisted of aromatase inhibitors (n=26) or tamoxifen (n=25)
with goserelin acetate (n=3) for premenopausal women.
Patients receiving chemotherapywere treatedwith cyclophos-
phamide, methotrexate and ﬂuorouracil (CMF; n=12) or an
anthracycline-based regimen (n=8).
3.5. Follow-up and statistical analysis
The median follow-up for all patients was 90.5 months (range:
7–152 months) and 94 months (range: 8–152 months) for sur-
viving patients. Patientswere seen every 3months in the ﬁrst 2
years after the treatment and every 6months thereafter.Mam-
mography, breast and abdominal ultrasound examinations,
chest X-ray, and blood tests were performed annually. In case
of uncertain mammography and ultrasound ﬁndings, breast
MRI and/or aspiration cytology of suspicious lesions were per-
formed to differentiate between LR and localized ﬁbrosis or
fat necrosis. LR was deﬁned as any detection of cancer in
the treated breast, proved by histological examination. All
intra-breast relapses, before or after the detection of distant
metastasis, were taken into account. An elsewhere breast fail-
ure (EBF) was deﬁned as an ipsilateral LR detected at least
2 cm from the surgical clips. All other intra-breast recurrences
were classiﬁed as true recurrence/marginalmiss (TR/MM). The
cosmetic results and late side effects were evaluated retro-
spectively. Cosmetic results were assessed using the Harvard
criteria.30 Skin side effects and ﬁbrosis were scored by the
RadiationTherapyOncologyGroup/EuropeanOrganization for
Research and Treatment of Cancer (RTOG/EORTC) late radia-
tion morbidity scoring scheme.31 All available mammography
ﬁlms were carefully reviewed for asymptomatic fat necrosis
(i.e. oil-cysts and/or coarse calciﬁcations).actuarial rates of speciﬁc events and survival were calculated
using the Kaplan–Meier method.32 Univariate Cox regression
analysis was used to evaluate the possible prognostic factors
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Table 3 – Incidence of ﬁrst events.
Event n (%)
Local recurrence 7 (7%)
TR/MM 2 (2%)
EBF 5 (5%)
Regional recurrence 1 (1%)
Supraclavicular failure 1 (1%)
Axillary failure 0 (0%)
Distant metastasis 15 (15%)
Any ﬁrst relapsea 23 (23%)
Contralateral breast cancer 2 (2%)
Second primary malignancy 5 (5%)
Non-breast cancer death 2 (2%)
TR/MM= true recurrence/marginal miss; EBF=elsewhere breast
failure.
a Any ﬁrst relapse= local, regional, or distant failure, whichever
Fig. 1 – Time to local and regional recurrence by
Kaplan–Meier estimates. LTC= local tumour control;
RTC= regional tumour control. 8-year LTC=93.0%. 8-year
RTC=97.6%.came ﬁrst.
for LR.33 A p-value of ≤0.05 was considered statistically sig-
niﬁcant. A trend to signiﬁcance was established at p values
>0.05–0.10. SOLO software (Department of Biometrics, Univer-
sity of California, LosAngeles, CA,USA)wasused for statistical
analyses.
4. Results
4.1. Treatment outcome
Overall, 7 patients (7%) developed ipsilateral breast failure and
all LR occurred as a ﬁrst event. LRs were classiﬁed as TR/MM
and EBF in 2 (2%) and 5 (5%) cases, respectively. Mean time
to TR/MM and EBF was 31.5 months (range: 10–53) and 81.2
months (range: 27–142), respectively. The crude rates of ﬁrst
events are summarized in Table 3. The 5- and 8-year actuarial
rate of LR was 4.5 and 7.0% (Fig. 1). The 8-year probability of
developing TR/MM and EBF was 2.2 and 4.8%, respectively. The
8-year LR rate with clear (>2mm), close (≤2mm), unknown,
and positive margin status was 4.9, 0, 0, and 46.7%, respec-
tively. A total of 2 (2%) regional nodal failures were observed
for an 8-year actuarial rate of 2.4% (Fig. 1). Both regional
nodal failures occurred as a supraclavicular failure. Axillary
recurrence was not observed during the follow-up period.
Disease-free survival (DFS), cancer-speciﬁc survival (CSS), and
overall survival (OS) at 8 years were 76.1, 82.8, and 80.4%,
respectively.
4.2. Salvage treatment and outcome for LR
Overall, at a median follow-up of 35 months (range: 3–120
months) after LR, ﬁve out of 7 patients (71.4%) were alive.
One patient with an inoperable diffuse multiplex LR received
palliative chemotherapy and died of the disease 39 months
after LR. The other 6 patients with LR were salvaged with
repeated BCS (n=4) or mastectomy (n=2). At the time of
analysis 2 patients in the re-excision group and 1 patient
in the mastectomy group were alive without any furtherrelapse at 20–120 months after LR. The other 3 women
(2 in the re-excision and 1 in the mastectomy groups)
developed a second LR and subsequent distant metastases
later and were treated with systemic treatments. Two of
them were alive with the disease 3 and 35 months after
LR and 1 woman died of her disease 56 months after
LR.
4.3. Prognostic factors for LR
On univariate analysis, among the evaluated patient- and
tumour-related parameters (e.g. menopausal status, age
groups: ≤50 years vs. older, oestrogen and progesterone recep-
tor status, histological type: ductal vs. all others, presence of
extensive intraductal component (EIC): yes vs. no, margin sta-
tus: negative vs. positive and clear (>2mm) vs. close (≤2mm),
tumour size: pT1 vs. pT2, histological and nuclear grade: grade
1–2 vs. 3) only positive margin status was signiﬁcantly asso-
ciated with the development of LR (p=0.007; 8-year LR rate
with negative and positive margins: 4.2% vs. 46.7%, respec-
tively). There was also a non-signiﬁcant trend for a higher LR
rate for patients with EIC positive tumours (p=0.067; 8-year LR
rate with EIC negative and positive tumours: 3.7% vs. 24.0%,
respectively). However, there was no signiﬁcant difference in
local tumour control between patients with clear (>2mm) and
close (≤2mm) surgical margins.
Among treatment-related parameters (e.g. number of
implant needles, number of implant planes, tumour bed dose:
low vs. high boost dose, and use of adjuvant systemic therapy)
there was a non-signiﬁcant trend for higher LR rate for those
patients treated with a lower tumour bed dose (p=0.073; 8-
year LR rate with low and high boost dose groups: 23.7% vs.
1.3%, respectively).
Due to the low number of events (n=2), no parameter
was signiﬁcantly associated with the development of TR/MM.
However, both true recurrences occurred in patients having
EIC positive tumours, associated with positive margins in one
case.
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Table 4 – Cosmetic results and late radiation side effects.
Variable n (%)
Cosmetic results (n=66)a
Excellent 11 (17%)
Good 26 (39%)
Fair 22 (33%)
Poor 7 (11%)
Skin side effects (n=91)b
Grade 0 67 (74%)
Grade 1 11 (12%)
Grade 2 11 (12%)
Grade 3 2 (2%)
Fibrosis (n=91)b
Grade 0 36 (39%)
Grade 1 26 (29%)
Grade 2 23 (25%)
Grade 3 6 (7%)
Fat necrosis (n=100)
Asymptomatic 24 (24%)
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a Data on cosmetic results were available for 66 patients.
b Data on late radiation side effects were available for 91 patients.
.4. Cosmetic results and side effects
ata on late radiation side effects were available for 91
atients (91%). Cosmetic results were documented for 66
atients (66%). Cosmetic results and late radiation side effects
re listed in Table 4. The rate of excellent/good cosmetic out-
omes was 56.1%. Severe (≥grade 3) side effects occurred in
nly 8 patients (8%), including 6 cases (6%) with grade 3 ﬁbro-
is and 2 (2%) with grade 3 telangiectasia. Neither of the 2
ymptomatic fat necroses required surgical intervention.
. Discussion
he standard technique of RT after BCS is to treat the whole
reast by teletherapywith tangential ﬁelds up to a total dose of
5–50Gy supplemented with an additional dose of 10–25Gy to
he tumour bed for selected high-risk patients.3,4 Based on the
nalysis of dose–response curves, Van Limbergen34 reported
hat above 50Gy, an increase of 15Gy would reduce the LR
ate by a factor of 2. To date, three randomized trials have
onﬁrmed that a boost dose of 10–16Gy after 50Gy WBI sig-
iﬁcantly decreased the LR rate (Table 5).4–8 Patient age less
Table 5 – Results of randomized “boost versus no boost” trials.
Clinical trial Patient
no.
Technique Boost dose
(Gy)
Med
(
EORTC5 5318 EBI/LDR BT 15–16 1
HNIO4,6,7 627 ELE/HDR BT 12–16
Lyon8 1024 ELE 10
EORTC=European Organization for Research and Treatment of Cancer;
period; LR= local recurrence; EBI = external beam irradiation (photons or e
BT=brachytherapy; NR=not reported.diotherapy 1 5 ( 2 0 1 0 ) 1–7 5
than 50 years, close, microscopically positive or unknown sur-
gical margins, and the presence of an extensive intraductal
component (EIC) are generally accepted as absolute indica-
tions for boost irradiation.4,34 However, a controversy still
exists regarding the optimal boost technique. Traditionally,
LDR BT or teletherapy using electron or photon beams has
been used to deliver the boost dose to the tumour bed.5,8–15,34
Later, HDR BT was also accepted as a safe alternative boost
modality (Table 6).4,6,7,12,16–27,34 Only a few reports have com-
pared the outcome in patients treated with BT or external
beam boost.6,7,9–15,20,21,25,35,36 In the majority of these studies
similar local control and cosmetic results have been reported
for women boosted either with interstitial implants or elec-
trons/photons. Recently, Knauerhase et al.25 reported that a
median dose of 10Gy HDR BT boost yielded a signiﬁcantly
lower 10-year actuarial LR rate compared to an external beam
boost (5.9% vs 12.5%; p=0.023). In the EORTC boost trial the 10-
year cumulative incidence of LR was 6.3% for the 1639 patients
who received an electron boost, 5.3% in the 753 patients who
received a photon boost and only 3.7% in the 225 patients who
had an interstitial LDR BT boost.36 The difference was not sig-
niﬁcant (p=0.13); however, the trial was not powered to detect
a possible difference in local control between different boost
modalities.
Based on our results, it seems that an interstitial HDR BT
boost can be used in the conservative therapy of breast cancer
with low incidence of late side effects and with at least similar
local tumour control as with percutaneous boost techniques.
The relatively low rate (56%) of good/excellent cosmetic results
can be explained by the relatively high (20Gy LDR-equivalent)
boost dose and high DNR value. On the other hand, this high
dose of HDRBT boostwas able tomask classical risk factors for
LR with the exception of positive margin status. Furthermore,
BT is preferable in some anatomical situations, especially in
cases of a deep-seated tumour bed in a large volume breast.
Obviously, BT offers the practical advantage of more confor-
mal treatment of small volumes with higher doses and lower
doses to the skin.4,34 Van Limbergen34 compared dose distri-
butions of 4.5–15MeV electron boosts to different settings of
interstitial implants. He found that for target depths reach-
ing beyond 28mm under the skin, interstitial implants had
a ballistic advantage, delivering signiﬁcantly lower skin doses
than electron beams. Thus, in addition to external beam boost
modalities multi-catheter HDR BT remains a standard treat-
ment option to deliver an additional dose to the tumour bed
after BCS and WBI.
ian FUP
years)
5-Year LR
boost vs. no
boost (%)
10-Year LR
boost vs. no
boost (%)
p-Value
0.8 4.3 vs. 7.3 6.2 vs. 10.2 <0.0001
5 6.3 vs. 13.3 NR 0.0017
3.3 3.6 vs. 4.5 NR 0.044
HNIO=Hungarian National Institute of Oncology; FUP= follow-up
lectrons); ELE=electrons; LDR= low-dose-rate; HDR=high-dose-rate;
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Table 6 – Results of HDR brachytherapy boost series.
Institution Patient no. RT scheme (fraction
no.×dose [Gy])
Median FUP
(years)
5-Year LR % Annual
LR %
Exc./good
cosmesis
%
Barcelona16 294 8–11×2–2.5 5.8 9 (9-year) 1.00 96
University Wien17 274 1×7–12 8.7 3.9 (10-year) 0.39 38
Brno18 215 1×8–12 5.8 1.5 0.30 73
Linz19 212 1×10 5.2 4.6 0.92 78
Saarbrücken20 202 1×12–15 >3 6.4a NA 85
TMH, Mumbai21 153 1×10 3 8 1.60 83
Valencia23 125 3×4.4 7 4.2 0.84 77
Paris24 108 2×5 3.75 5.1 1.02 63
University Rostock25 75 1×8–12 7.8 5.9 (10-year) 0.59 NR
Virgina C. University27 18 6×2.5 4.2 0 0 67
Present study 100 3×4–4.75; 1×8–10.35 7.8 7.0 (8-year) 0.88 56
=Tat
rAll patients 1776
RT= radiotherapy; FUP= follow-up period; LR= local recurrence; TMH
a Crude rate.
6. Conclusions
Fractionated HDR BT boost using multi-catheter implants
provides excellent long-term local tumour control with
acceptable cosmetic outcome and low rate of grade 3 late radi-
ation side effects. Our results conﬁrm that high-dose HDR BT
boost canmask classical risk factors for LR (with the exception
of positive margins).
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